Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25] (S0959804917309334) (10.1016/j.ejca.2017.05.001))

Ian Chau, Markus Peck-Radosavljevic, Christophe Borg, Peter Malfertheiner, Jean Francois Seitz, Joon Oh Park, Baek Yeol Ryoo, Chia-Jui Yen, Masatoshi Kudo, Ronnie Poon, Davide Pastorelli, Jean Frederic Blanc, Hyun Cheol Chung, Ari D. Baron, Takuji Okusaka, L. Bowman, Zhanglin Lin Cui, Allicia C. Girvan, Paolo B. Abada, Ling YangAndrew X. Zhu

Research output: Contribution to journalComment/debate

2 Citations (Scopus)

Abstract

The authors regret that, in Fig. 4, a hazard ratio was missing for the FHSI-8 symptom item Discomfort or Pain in Stomach. Please see the corrected figure here. [Figure presented] The authors would like to apologise for any inconvenience caused.

Original languageEnglish
Pages (from-to)135-136
Number of pages2
JournalEuropean Journal of Cancer
Volume100
DOIs
Publication statusPublished - 2018 Sep 1

Fingerprint

Hepatocellular Carcinoma
Stomach
Emotions
Pain
Therapeutics
corrigendum
sorafenib
ramucirumab

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Chau, Ian ; Peck-Radosavljevic, Markus ; Borg, Christophe ; Malfertheiner, Peter ; Seitz, Jean Francois ; Park, Joon Oh ; Ryoo, Baek Yeol ; Yen, Chia-Jui ; Kudo, Masatoshi ; Poon, Ronnie ; Pastorelli, Davide ; Blanc, Jean Frederic ; Chung, Hyun Cheol ; Baron, Ari D. ; Okusaka, Takuji ; Bowman, L. ; Cui, Zhanglin Lin ; Girvan, Allicia C. ; Abada, Paolo B. ; Yang, Ling ; Zhu, Andrew X. / Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib : Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25] (S0959804917309334) (10.1016/j.ejca.2017.05.001)). In: European Journal of Cancer. 2018 ; Vol. 100. pp. 135-136.
@article{05ae336a83dc4104878299d2bf8bf4a0,
title = "Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25] (S0959804917309334) (10.1016/j.ejca.2017.05.001))",
abstract = "The authors regret that, in Fig. 4, a hazard ratio was missing for the FHSI-8 symptom item Discomfort or Pain in Stomach. Please see the corrected figure here. [Figure presented] The authors would like to apologise for any inconvenience caused.",
author = "Ian Chau and Markus Peck-Radosavljevic and Christophe Borg and Peter Malfertheiner and Seitz, {Jean Francois} and Park, {Joon Oh} and Ryoo, {Baek Yeol} and Chia-Jui Yen and Masatoshi Kudo and Ronnie Poon and Davide Pastorelli and Blanc, {Jean Frederic} and Chung, {Hyun Cheol} and Baron, {Ari D.} and Takuji Okusaka and L. Bowman and Cui, {Zhanglin Lin} and Girvan, {Allicia C.} and Abada, {Paolo B.} and Ling Yang and Zhu, {Andrew X.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.ejca.2018.06.002",
language = "English",
volume = "100",
pages = "135--136",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",

}

Chau, I, Peck-Radosavljevic, M, Borg, C, Malfertheiner, P, Seitz, JF, Park, JO, Ryoo, BY, Yen, C-J, Kudo, M, Poon, R, Pastorelli, D, Blanc, JF, Chung, HC, Baron, AD, Okusaka, T, Bowman, L, Cui, ZL, Girvan, AC, Abada, PB, Yang, L & Zhu, AX 2018, 'Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25] (S0959804917309334) (10.1016/j.ejca.2017.05.001))', European Journal of Cancer, vol. 100, pp. 135-136. https://doi.org/10.1016/j.ejca.2018.06.002

Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib : Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25] (S0959804917309334) (10.1016/j.ejca.2017.05.001)). / Chau, Ian; Peck-Radosavljevic, Markus; Borg, Christophe; Malfertheiner, Peter; Seitz, Jean Francois; Park, Joon Oh; Ryoo, Baek Yeol; Yen, Chia-Jui; Kudo, Masatoshi; Poon, Ronnie; Pastorelli, Davide; Blanc, Jean Frederic; Chung, Hyun Cheol; Baron, Ari D.; Okusaka, Takuji; Bowman, L.; Cui, Zhanglin Lin; Girvan, Allicia C.; Abada, Paolo B.; Yang, Ling; Zhu, Andrew X.

In: European Journal of Cancer, Vol. 100, 01.09.2018, p. 135-136.

Research output: Contribution to journalComment/debate

TY - JOUR

T1 - Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib

T2 - Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25] (S0959804917309334) (10.1016/j.ejca.2017.05.001))

AU - Chau, Ian

AU - Peck-Radosavljevic, Markus

AU - Borg, Christophe

AU - Malfertheiner, Peter

AU - Seitz, Jean Francois

AU - Park, Joon Oh

AU - Ryoo, Baek Yeol

AU - Yen, Chia-Jui

AU - Kudo, Masatoshi

AU - Poon, Ronnie

AU - Pastorelli, Davide

AU - Blanc, Jean Frederic

AU - Chung, Hyun Cheol

AU - Baron, Ari D.

AU - Okusaka, Takuji

AU - Bowman, L.

AU - Cui, Zhanglin Lin

AU - Girvan, Allicia C.

AU - Abada, Paolo B.

AU - Yang, Ling

AU - Zhu, Andrew X.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - The authors regret that, in Fig. 4, a hazard ratio was missing for the FHSI-8 symptom item Discomfort or Pain in Stomach. Please see the corrected figure here. [Figure presented] The authors would like to apologise for any inconvenience caused.

AB - The authors regret that, in Fig. 4, a hazard ratio was missing for the FHSI-8 symptom item Discomfort or Pain in Stomach. Please see the corrected figure here. [Figure presented] The authors would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85049333639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049333639&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2018.06.002

DO - 10.1016/j.ejca.2018.06.002

M3 - Comment/debate

C2 - 29970352

AN - SCOPUS:85049333639

VL - 100

SP - 135

EP - 136

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -